Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects

Phase 1

Completed

• Conditions: Healthy

• Registration Number: NCT00447681
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

This a randomized, double-blind placebo-controlled inpatient/outpatient, sequential group study of ascending single IV doses of ILV-094, an investigational drug, administered to healthy subjects. In addition, there will be one sub-cutaneous dose cohort, which will follow the 25 mg IV dose.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-12
• Study First Submitted: 2007-03-13
• Study First Submitted QC: 2007-03-14
• Study First Posted: 2007-03-15
• Study Completion: 2007-11
• Status Verified: 2007-12
• Last Update Submitted: 2007-12-11
• Last Update Posted: 2007-12-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
To evaluate the safety, tolerability, pharmacokinetics and pharmcodynamics